

# Treatable traits in acute exacerbations of chronic airway diseases

Chronic Respiratory Disease  
Volume 16: 1–16  
© The Author(s) 2019  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/1479973119867954  
journals.sagepub.com/home/crd



Vanessa M McDonald<sup>1,2</sup>, Christian R Osadnik<sup>3,4</sup>  
and Peter G Gibson<sup>1,2</sup>

## Abstract

Acute exacerbations of chronic airway disease are common occurrences that cause a major burden of illness. Acute exacerbations are associated with impaired health status, increased lung function decline, hospitalization and increased risk of death. Exacerbation avoidance is a major priority. Despite this goal, exacerbations continue to occur and the need for effective models of care that optimize patient outcomes are urgently needed. 'Treatable Traits' is an approach to personalized medicine that has been proposed for the management of airway diseases. The treatable traits approach allows for the recognition of clinically important, identifiable and treatable disease characteristics, followed by targeted and individualized treatment interventions to address each trait. We review the literature relating to treatable traits in airway diseases; in particular, those traits that can predict exacerbations and approaches to management that aim to prevent exacerbations by using a treatable traits model of care. We propose this approach as a potentially useful model of care to both prevent and manage acute exacerbations.

## Keywords

Acute exacerbations, chronic airway disease, asthma, COPD, bronchiectasis, treatable traits

Date received: 25 June 2019; accepted: 9 July 2019

## Introduction

Chronic airway diseases are common and have a significant burden on affected individuals, their families and health-care systems.<sup>1</sup> Worldwide, lung conditions are one of the most frequent causes of death.<sup>2</sup> The breadth of conditions that fall under the term of a chronic airway disease include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and bronchiectasis. Each disease is characterized by acute exacerbations, defined as an acute worsening of respiratory symptoms that require a treatment change. These events range from mild to severe.

Exacerbations impose major negative health impacts upon individuals and a high cost burden upon society. Exacerbations are important as they speed the progression of disease, increase the decline in lung function and are related to significantly greater risk of hospitalization and mortality in asthma, COPD and

bronchiectasis.<sup>1,3</sup> Exacerbations therefore are highly important events. The major goals of management in chronic airway diseases are exacerbation prevention

<sup>1</sup> Priority Research Centre for Healthy Lungs and Centre of Excellence in Severe Asthma, Faculty of Health and Medicine, University of Newcastle, New South Wales, Australia

<sup>2</sup> Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia

<sup>3</sup> Department of Physiotherapy, Monash University, Melbourne, Australia


<sup>4</sup> Monash Lung and Sleep, Monash Health, Melbourne, Australia

## Corresponding author:

Vanessa M McDonald, Priority Research Centre for Healthy Lungs and Centre of Excellence in Severe Asthma, Faculty of Health and Medicine, University of Newcastle, Level 2 West Wing, 1 Kookaburra Circuit, New Lambton Heights, New South Wales 2305, Australia.

Email: [vanessa.mcdonald@newcastle.edu.au](mailto:vanessa.mcdonald@newcastle.edu.au)





**Figure 1.** Treatable traits domains and criteria to be considered a trait. Figure reproduced with permission from the Centre of Excellence in Severe Asthma (<https://www.severeasthma.org.au>)

and prompt and effective management of exacerbations when they do occur.

COPD, asthma and bronchiectasis are complex. They each have diverse aetiology and disease mechanisms, and manifest a range of symptoms. The impact of each disease on individual patients is also heterogeneous, which means that not all disease manifestations occur in every person, or in the same person at all times. This heterogeneity and complexity has led to the recognition that treatment approaches cannot be ‘one size fits all’, but individualized strategies to patient care are needed, or in other words, personalized medicine approaches for chronic airway diseases.<sup>4–7</sup> The ‘Treatable traits’ strategy is an approach that has been proposed as a way to implement personalized medicine for chronic airway disease. Treatable traits are disease characteristics that are clinically relevant, identifiable and modifiable (Figure 1).<sup>4,5,7</sup> In this review, we will examine the potential application of a treatable trait strategy for patients with chronic airway diseases, namely COPD, asthma and bronchiectasis, as these are the conditions where the treatable traits strategy has been proposed. Typically, the treatable traits concept has been applied to the management of adults with asthma and COPD in their stable phase. Our focus is to explore the application of treatable traits as predictors of exacerbations and during acute exacerbations of adults with airway diseases.

## The burden of chronic airway disease

Chronic airway diseases have a significant burden, with persistent symptoms, reduced health-related quality of life (HRQoL), associated morbidity and mortality and associated health-care costs.

Asthma directly affects an estimated 330 million people worldwide,<sup>8</sup> of which approximately 3–10% have severe treatment-refractory disease.<sup>9,10</sup> People

with severe asthma experience uncontrolled symptoms,<sup>11</sup> impaired quality of life,<sup>12,13</sup> frequent exacerbations, hospitalizations<sup>14</sup> and are at increased risk of death.<sup>15</sup> Asthma also places a substantial financial burden on both individuals (e.g. medication costs and reduced work capacity) and society (e.g. health-care costs, reduced workplace productivity).<sup>16–18</sup> Asthma exacerbations are responsible for 0.6% of all hospital admissions in Europe, as well as lost time at work/school,<sup>18</sup> and death.<sup>15</sup> In 2016, the Global Burden of Disease collaboration estimated that 420,000 people in the world died from asthma, that is, more than 1000 deaths worldwide per day.<sup>19</sup>

An estimated 251 million people worldwide have COPD, based on WHO estimates.<sup>20</sup> COPD is currently the third leading cause of mortality worldwide,<sup>21</sup> with over 3 million reported deaths in 2016 (5.4% of all global deaths).<sup>20</sup> Acute exacerbations occur in up to half of patients and approximately 20% require hospitalization.<sup>22</sup> COPD is the second leading cause of preventable hospital admissions, with rates of admission predicted to exceed that of ischaemic heart disease within the next 5 years.<sup>23</sup> In 2016–2017 in Australia 78,000 potentially preventable hospital admissions were recorded.<sup>24</sup> It is therefore unsurprising that COPD is associated with poorer HRQoL, worse functional impairment and significant healthcare costs.

The burden of bronchiectasis is becoming increasingly recognized worldwide; however, there remains a paucity of prevalence data. Quint et al. sought to determine the incidence and prevalence of bronchiectasis in adults from the United Kingdom, between 2004 and 2013 and identify its impact upon mortality. Using data from the Clinical Practice Research Data-link, a large computerized database of longitudinal primary care medical records, they report increasing bronchiectasis incidence and prevalence. The point prevalence of bronchiectasis increased in women from 350.5 per 100,000 people in 2004, to 566.1 per 100,000 people in 2013. Similarly in men, the prevalence increased from 301.2 per 100,000 people in 2004, to 485.5 per 100,000 people in 2013.<sup>25</sup> These rates increased over the study time and were higher in older people. Another large study from Germany estimated the prevalence of bronchiectasis to be slightly lower (an estimated 67 cases per 100,000 in 2013).<sup>26</sup>

## Acute exacerbations

Exacerbations or lung attacks are a major contributor to disease burden across these chronic airway

diseases.<sup>27</sup> Exacerbations refer to episodes of acute worsening of disease symptoms, which commonly result in increased healthcare use, hospitalizations, reduced quality of life and may cause death.

In adults with asthma, exacerbations are a major cause of morbidity.<sup>28</sup> Exacerbations are most common in uncontrolled asthma and can be triggered by pathogen (e.g. virus and/or bacteria), allergen or occupational exposures, stress or sub-optimal adherence to preventer medications.<sup>29</sup> Epidemics of severe asthma exacerbations can also be triggered by major environmental events, such as wildfire smoke or thunderstorm events, which trigger high levels of respirable pollen allergens.<sup>30,31</sup>

In COPD, exacerbations are typically triggered by infections (viral or bacterial) or air pollutant exposure. COPD exacerbations commonly lead to hospitalization, accelerated lung function decline, poor health status and increased mortality.<sup>32</sup> In fact, in COPD, the mortality risk at 1 year following a hospitalization for an acute exacerbation is approximately 25%,<sup>33,34</sup> which is greater than the mortality risk of someone hospitalized for an acute myocardial infarction.<sup>35</sup>

Exacerbations are also a cardinal feature of bronchiectasis, where they are associated with more severe disease and chronic colonization of the airway with pathogenic bacteria such as *Pseudomonas aeruginosa*.<sup>36</sup> Despite exacerbations being a feature of the natural history of this disease, these events are not without consequence. In a prospective cohort study of 608 patients with bronchiectasis Chalmers et al. reported that patients with three or more exacerbations per year have double the mortality rate of those who do not experience exacerbations (hazard ratio 2.03 (95% confidence interval 1.02–4.03)). In addition to the associated mortality risk, acute exacerbations in bronchiectasis also significantly impact HRQoL.<sup>37</sup>

These data confirm that acute exacerbations of airway disease are common occurrences with significant consequences. Exacerbations are associated with increased decline in lung function, poor quality of life and increased mortality. The avoidance of attacks in chronic airway disease is therefore imperative, a point highlighted in the recent Lancet commission on asthma, which called for zero tolerance of attacks, with an emphasis on precision medicine rather than a one-size-fits-all approach to treatment and secondary prevention. They also call for an abandonment of the terms exacerbations and flare ups, in favour of attacks, in an effort to change our weak responses to

these sentinel events.<sup>1</sup> Precision medicine requires measurement of biomarkers to determine individual treatable traits, and when applied in the context of exacerbation prevention, it is hoped that this will identify at-risk patients and perhaps empower patients in their treatment decisions towards the commitment to individualized life-long prophylactic treatment.<sup>1</sup>

While strategies to optimize long-term management of chronic airway disease have steadily improved, approaches that limit the impact of acute exacerbations have lagged. We do know however that in asthma, COPD and bronchiectasis, the best predictor of future attacks is the history of a previous one.<sup>37–39</sup> Identifying this trait in patients and focusing on avoidance of exacerbations through individualized and effective treatments, adherence, self-management strategies and education, public health messages, and new drug discovery and development is a way to move forward in secondary prevention strategies.

### **Treatable traits: An emerging approach for chronic airway disease management**

The concept of treatable traits in airway diseases has developed over the last decade following recognition that asthma and COPD are complex syndromes which require individualized assessment, investigation and treatment.<sup>5,6,40</sup> The treatable trait strategy was initially proposed in 2016,<sup>5</sup> building on previous work that proposed multidimensional assessment and treatment approaches for individual respiratory diseases, for example, in asthma.<sup>6</sup> Subsequent international workshops have been convened to seek expert consensus on how to apply and progress a treatable traits strategy for clinical management.<sup>4,7</sup> While proposed for management in stable disease, the principles of treatable traits easily fit within management of acute exacerbations. Notably assessment of traits in stable disease can also identify important predictors of future attacks and hence identify treatment targets for exacerbation prevention. However, while this has been proposed,<sup>38</sup> it has not yet been tested in efficacy studies.

The treatable traits strategy incorporates a number of elements. Inherent to its approach is a multidimensional assessment of each individual patient to determine which traits exist in that patient. Traits are categorized into the three domains of pulmonary traits, extra-pulmonary traits and behaviours/lifestyle risk factors of airway diseases (Figure 1).

Multidimensional assessment can be used to identify the range of traits within an individual and involves a clinical history and examination, an evaluation of risk factors, and measurement of spirometry, FeNO and blood eosinophils. Following this, if the probability of airway disease is high, irrespective of the disease label, assessment of treatable traits followed by individualized management is recommended.<sup>5</sup> The Treatable traits strategy aims to support an individualized and targeted treatment approach, which is broadly applicable independent of disease diagnosis. This is in contrast to current guideline-based recommendations that are disease specific.

A treatable trait can be defined as a therapeutic target identified by phenotypes or endotypes through a validated biomarker.<sup>5</sup> The biomarker is not necessarily a specific molecule but also includes findings from other assessment techniques such as imaging, lung function or patient-reported outcome measures.<sup>7</sup> In the treatable traits paradigm, these are referred to as trait identification markers (TIMs).<sup>7</sup>

Important to the treatable traits approach is the recognition that a given patient is likely to have multiple traits, and that each of these traits is important. In a population of patients with stable obstructive airway disease who underwent a multidimensional assessment of traits, we reported that the mean (SD) number of traits identified was 11.3 (2.5). Furthermore, each additional trait identified was associated with a clinically important decrement in HRQoL.<sup>41</sup> The temporal stability of traits in patients with chronic airway disease is not known, and we expect that traits will differ during different stages of the disease course. This is particularly important if the treatable traits strategy is to be applied during acute attacks.

To be considered a candidate treatable trait there are three characteristics that must be fulfilled. A trait must (1) have clinical relevance, (2) be identifiable and measurable and (3) be treatable (Figure 1).<sup>7</sup>

Personalized medicine has been defined as an approach where treatments are targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient.<sup>42</sup> Essential in this definition is the goal of improving clinical outcomes for individual patients and minimizing unnecessary side effects for those less likely to have a response to a particular treatment.<sup>42</sup> The treatable traits strategy is a vehicle for the implementation of such an approach as it importantly recognizes that chronic airway diseases are heterogeneous, multisystem diseases that require

patients to be active participants in their disease management. Proposed traits that are relevant to exacerbations of chronic airway diseases are presented in Table 1.

A further aspect of treatable traits is the possibility of using a 'label-free' approach to airway disease management. This approach recognizes the similarities in the different obstructive airway diseases, and their significant overlap. This means that an individual may have diagnostic features of more than one disease. This has been explicitly described in asthma and COPD, where the asthma-COPD overlap syndrome has been extensively studied.<sup>43</sup> However, it is also recognized that bronchiectasis can overlap with asthma and/or COPD.<sup>44</sup> Since acute attacks are a feature of each of the obstructive airway diseases, there may be value in using a label-free approach in assessing and managing these events.

### *Applying a treatable traits approach to exacerbations of chronic airway disease*

Many potential treatable traits have been proposed in the treatable trait strategy. In the 2016 proposal by Agusti et al., there were 31 traits presented.<sup>5</sup> In the Lancet commission on asthma, which also recommends the treatable traits approach, there were 14 traits identified,<sup>1</sup> and in the multidimensional assessment and individualized management of asthma in the elderly, Gibson et al. proposed 22 traits.<sup>6</sup> As previously stated, these were considered in stable disease; however, many traits either predict future exacerbation or have relevance during acute exacerbations.

To date there are no randomised controlled trials (RCTs) in acute exacerbations that have applied a broad treatable traits approach to identify relevance of multiple individual traits to disease outcomes or that evaluate how to prioritize assessment and treatments. RCTs of the treatable traits approach are needed. In a proof of concept study, McDonald et al. applied a multidimensional assessment and individualized management targeted to identified traits in a stable COPD population. The intervention resulted in major improvements in health status (14 unit improvement in the St. George Respiratory Questionnaire for the intervention group versus 2.2 unit for the control), and biological outcomes (high sensitivity C-Reactive Protein (hsCRP), sputum eosinophils and neutrophil counts). While there were trends for fewer exacerbations this was not significant, although the numbers were small ( $N = 34$ ).<sup>45</sup>

**Table 1.** Treatable traits relevant to exacerbations of chronic airway diseases.

Treatable Trait	Trait Identification Marker	Relevance to acute exacerbations	Treatment options during acute exacerbations
<b>Pulmonary traits</b>			
Type-2 inflammation	Sputum eosinophils $\geq 3\%$ , blood eosinophils $\geq 0.3 \times 10^9/L$ , FeNO $\geq 40$ ppb.	Eosinophilic inflammation and increased expression of type-2 inflammatory markers (e.g. IL-5, IL-13 and FeNO) are elevated in a subset of patients with chronic airway disease. Eosinophilic and type-2 inflammation are associated with increased exacerbation risk. <sup>52,77,78</sup>	Oral corticosteroids, anti-IgE, anti-interleukin-5, -13, -4
Infection and pathogen colonization	Presence of bacterial pathogen and/or identified virus via sputum culture, sputum PCR.	Lung infections by either viruses or bacteria trigger exacerbations of chronic lung diseases. Respiratory virus infection causes a worsening of asthma symptoms, with the majority of exacerbations caused by rhinovirus in both children and adults. <sup>79,80</sup> Exacerbations of COPD are also commonly associated with respiratory viral infections. <sup>81,82</sup> Bacterial infection is associated with exacerbations in asthma. <sup>83–85</sup>	Antibiotics (Macrolides/Tetracyclines)
Airflow limitation	FEV <sub>1</sub> /FVC <0.7 and FEV <sub>1</sub> <80% predicted.	More severe airflow limitation is associated with increased risk of exacerbations. Exacerbations lead to worsening airflow limitation.	Bronchodilators, Smoking cessation
Chronic bronchitis	Cough and sputum for 3 consecutive months over 2 years.	Mucus hypersecretion is associated with higher rates of acute exacerbation, hospitalization and death.	Smoking cessation, macrolides, muco-ciliary clearance techniques. Carbocysteine, Roflumilast.
<b>Extrapulmonary traits</b>			
Upper airway disease	History and examination, suggestive symptoms, CT, nasendoscopy-SNOT 22: or total rhinitis score 1–4.	In asthma, upper airway disease is a predictor of future exacerbation. <sup>38</sup>	Topical steroids, Leukotriene receptor antagonists, antihistamines
Vocal cord dysfunction	Fibre optic laryngoscopy, flow-volume curve, dynamic neck CT, VCD questionnaire, for example, Pittsburgh $\geq 4$ .	Vocal cord dysfunction can mimic symptoms of asthma during acute attacks, complicating assessment and management. In asthma, vocal cord dysfunction is a predictor of future exacerbation. <sup>38</sup>	Speech pathology therapy
Obstructive sleep apnoea	Screening – Stop Bang ( $\geq 3$ ), diagnostic – polysomnography.	Obstructive sleep apnoea is a predictor of future exacerbation. <sup>38</sup> Poor sleep quality is also associated with increased exacerbation risk in COPD. <sup>86</sup>	Continuous positive airway pressure, Weight loss, Mandibular advancement splint
Cardiovascular disease	Consistent clinical profile supported by: Chest radiography (dynamic cardiac CT), echocardiogram, NT-proBNP >1000 pg/mL. Electrocardiogram, Doppler echocardiography.	COPD is associated with high cardiovascular mortality. <sup>87</sup>	Angiotensin-converting enzyme inhibitors, diuretics, $\beta$ -blockers

(continued)

Table 1. (continued)

Treatable Trait	Trait Identification Marker	Relevance to acute exacerbations	Treatment options during acute exacerbations
Anxiety/ Depression	Psychologist/psychiatrist assessment, screening questionnaires, for example, HADS anxiety/depression domain score $\geq 11$ .	Anxiety and depression are predictors of acute exacerbations in asthma and COPD. <sup>38,88</sup>	Anxiety management, breathing retraining, anxiolytic/antidepressant medication, psychotherapy
Persistent systemic inflammation	Elevation of at least two systemic inflammatory markers on more than one occasion, for example, high sensitivity CRP $> 3$ mg/L and WCC $> 9 \times 10^9$ /L.	Persistent systemic inflammation is associated with more comorbidities, increased hospitalization and death in COPD. <sup>89</sup> Systemic inflammation predicts future exacerbation in asthma. <sup>38</sup>	Statins <sup>a</sup> Weight loss Physical Activity
Cachexia	FFMI of $<15$ kg/m <sup>2</sup> for women and $16$ kg/m <sup>2</sup> for men, ASMMI of $<5.45$ kg/m <sup>2</sup> for women and $<7.26$ kg/m <sup>2</sup>	Common in hospitalized COPD patients and presents a significant burden with malnourished patients having an increased risk of hospitalization, longer length of stay and increased risk of readmission. <sup>90</sup>	Diet, oral nutritional supplements, physical activity
Frailty	Fried frailty phenotype (slowness, exhaustion, low activity, unexplained weight loss, weakness) score $\geq 3$ <sup>68</sup> FRAIL scale $\geq 3$ <sup>91</sup>	Frailty is estimated to occur in $>40\%$ of patients with AECOPD and associates with increased risk of readmission <sup>74</sup>	Predominantly delivered after discharge. In stable COPD, resolution of frailty in patients who attended PR occurred in 71/115 (62%). <sup>70</sup>
Impaired physical function: - Muscle weakness - Sarcopenia - Exercise intolerance - Physical inactivity/sedentary behaviour	Dynamometry (portable/computerized) or strain gauge measures $<80\%$ of predicted value using reference equations derived from similar population). Probable if low muscle strength (handgrip $<27$ kgs for males; $<16$ kgs for females or 5-rep chair rise $>15$ s); Confirmed if also low muscle quantity or quality (DEXA/BIA appendicular skeletal mass $<20$ kg for males; $<15$ kg for females). 6-minute walk distance $<350$ m or $<80\%$ of predicted value using appropriate reference equations for specific population. <sup>92</sup> $<7000$ steps/day via objective monitor <sup>93,94</sup> ; 'Low' score on International Physical Activity Questionnaire; Failure to	Quadriceps weakness during AECOPD only partially recovers 3 months after discharge. <sup>95</sup> Handgrip weakness associates with increased risk of respiratory-related hospitalization. <sup>96</sup> Sarcopenia associated with increased cost of care during hospitalisations, increased length of stay, readmission risk <sup>97</sup> and mortality <sup>98</sup> in older patients. Low muscle mass identified during AECOPD shown to associate with increased risk of 12-month mortality. <sup>99</sup> Lower 6-minute walk distance at discharge from AECOPD associates with increased risk of readmission. <sup>100</sup> Physical activity are shown to be excessively low during AECOPDs <sup>101,102</sup> and do not spontaneously recover. Physical activity levels are strong, independent predictors of hospital admissions and mortality in COPD. <sup>103-105</sup> Interactions occur between the benefits of physical activity and the harms of sedentary behaviour. <sup>106</sup>	Resistance training performed during hospitalized AECOPDs can prevent the decline in quadriceps weakness. <sup>107</sup> Exercise training during stable state can improve peripheral muscle weakness of several muscle groups. <sup>108-110</sup> Resistance training, dietary supplementation, particularly if BMI is low. Typically managed via longer-term programs in the outpatient setting. <sup>111</sup> Pulmonary rehabilitation delivered in the period soon after discharge significantly improves exercise capacity, QoL and reduced risk of readmission. <sup>112</sup> Evidence is currently lacking to guide best practice to improve low physical activity levels

(continued)

**Table 1.** (continued)


Treatable Trait	Trait Identification Marker	Relevance to acute exacerbations	Treatment options during acute exacerbations
	meet local public health physical activity/ sedentary behaviour guidelines.		experienced/detected during acute respiratory exacerbations. Research into the impact and reversibility of sedentary behaviour is in its relative infancy in many areas of respiratory medicine.
<b>Behavioural/risk factors</b>			
Previous exacerbations	≥2 respiratory-related antibiotic or oral corticosteroid courses in 12 months.	Prior exacerbation is one of the strongest predictors of future exacerbation in airway diseases.	Preventing exacerbations through vaccination, self-management education and avoidance strategies.
Inhaler use	Direct observation and standardized assessment, technique rated as inadequate, drug concentrations medication review, prescription of ≥3 different inhaler device types.	Suboptimal inhaler technique and inhaler device polypharmacy are both associated with increased health-care utilization. <sup>113</sup> Optimization of technique and rationalization of devices during acute events is important.	Education and treatment adjustment as needed.
Smoking	Self-report and exhaled CO ≥10 ppm, Urinary cotinine	Smoking is a risk factor for exacerbation, and smoking cessation reduces lung function decline and future risk of exacerbations. As such intervening with smoking cessation strategies during acute episodes is integral and opportunistic. <sup>114,115</sup>	Cessation support, nicotine replacement Antidepressants.
Adherence	Self-report, prescription records, electronic monitoring devices, <sup>116</sup> FeNO suppression test <sup>117</sup>	Good adherence is associated with fewer severe exacerbation in asthma and COPD. <sup>118,119</sup> The period of an acute exacerbation is an opportunistic period to review adherence.	Understanding reason for non-adherence and directing education of adherence aiding strategies accordingly.
Family and social support	Interview	Poor family and social support and deprived socio-economic status is associated with increased symptom deterioration and exacerbation. <sup>115,120</sup>	Activate support services.
Exposures (biomass/air pollution)	Exhaled carbon monoxide. Interview to assess exposures.	The association between air pollution and acute exacerbations of airway disease is well recognized, and is a major public health problem. <sup>121</sup>	Primary prevention is the goal. Treatment after exposure involves removing or minimizing exposures.

VCD: vocal cord dysfunction; COPD: chronic obstructive pulmonary disease; AECOPD: acute exacerbation of COPD.

<sup>a</sup>Research setting.

Other studies have tested interventions that target a specific trait, with positive effects. The inflammation studies of Green et al.,<sup>46</sup> Jayaram et al.<sup>47</sup> and Powell et al.<sup>48</sup> are good examples of treatment targeted to the T2 inflammation pathway, that is, using sputum eosinophil counts or FeNO to identify the

trait and direct treatment decisions accordingly. When treatment was titrated according to these biomarkers, attacks were reduced by at least 40%. These studies show support for the treatable traits approach in a stable population. They demonstrate that a treatable traits approach can be used as secondary



**Figure 2.** Treatable traits that predict future attacks in asthma. *Source:* Reproduced with permission of the © ERS 2019: European Respiratory Journal 53 (5) 1802058; DOI:10.1183/13993003.02058-2018 Published 9 May 2019. Adapted with permission Repirology.<sup>38</sup>

prevention of attacks in asthma and COPD. These promising results identify a need for more research, with the acute care setting being relevant.

A range of treatable traits have been linked to exacerbations in asthma, COPD and bronchiectasis. In asthma, a 2019 study that evaluated patients with severe asthma and a non-severe comparison group with well controlled asthma from the Australasian Severe Asthma Web-based Database reported 24 traits that could be identified.<sup>38</sup> In this study, participants underwent a baseline assessment and were followed up prospectively every 6 months for up to 2 years. Using negative binomial regression analysis, 10 traits that predicted future exacerbation risk were identified. The biggest predictor of future attack was being exacerbation prone. Other traits that predicted future exacerbation in asthma were depression, inhaler device polypharmacy, vocal cord dysfunction (VCD), obstructive sleep apnoea (OSA), eosinophilic inflammation, anxiety, systemic inflammation, upper airway disease and being underweight (Figure 2).<sup>38</sup> Targeting treatment to such traits with the highest risk profile may reduce exacerbation frequency and severity in an asthma setting, but this approach is yet to be evaluated.

The Evaluation of COPD Longitudinally to Identify Predictive Secondary End-points (ECLIPSE) study identified COPD phenotypes specifically relevant to acute exacerbations.<sup>49,50</sup> A ‘frequent exacerbation’ population, which was not dependent on disease severity, was predicted by previous exacerbation history and associated with impaired health status, history of gastro-oesophageal reflux disease and increased white blood cell counts.<sup>39</sup> A further study identified subtypes termed severe respiratory COPD (at elevated risk of severe exacerbations), moderate respiratory COPD and systemic COPD.<sup>51</sup> Elevated eosinophilic inflammation was associated with increased risk of severe exacerbations among people with COPD in the general population.<sup>52</sup> Further biomarkers that predicted exacerbation risk include C-reactive protein (CRP) and procalcitonin.<sup>50</sup>

### *Treatable traits in acute exacerbations*

Acute exacerbations of airway disease are complex and heterogeneous events. Studies that investigate the heterogeneity of acute exacerbations identify several distinct traits. A study of patients with acute exacerbations of COPD in hospital used imaging and



diagnostic biomarker assessment to characterize patients and suggested that elevated CRP levels may indicate pneumonia, while elevated NT-proBNP may indicate cardiac dysfunction.<sup>53</sup> A further attempt to phenotype COPD patients using molecular microbiological techniques identified bacteria- and virus-positive groups or pathogen-negative patient groups.<sup>54</sup> Among this population already in hospital with an acute exacerbation of COPD, the bacteria-positive subgroup had the best prognosis and the pathogen-negative group had the worst prognosis.<sup>54</sup>

More recently, Prins et al. reported the results of an RCT where CRP was used as a biomarker to direct antibiotic treatment in patients admitted to hospital with an acute exacerbation of COPD. Patients were randomized to receive biomarker directed antibiotic treatment if CRP was  $\geq 50$  mg/L ( $n = 101$ ) or guideline-based antibiotic treatment according to patient reported symptoms ( $n = 119$ ). Fewer antibiotics were prescribed in the CRP guided group (31.7% vs. 46.2%,  $p = 0.028$ ; adjusted odds ratio (OR) 0.178 [95% CI 0.077–0.411],  $p = 0.029$ ). There were no differences in 30-day treatment failures or time to first exacerbation. This novel study provides support for biomarker-driven antibiotic treatment targeting a treatable trait during acute exacerbations.<sup>55</sup>

In a study by Bafadhel et al. who sought to characterize acute exacerbation clusters in a group of 145 outpatients with COPD experiencing 183 exacerbations, the clusters identified were bacterial-, viral-, or eosinophilic-predominant, and a fourth, ‘pauci-inflammatory’ (associated with limited changes in the inflammatory profile).<sup>56</sup> These clusters were otherwise clinically indistinguishable and thus highlight the importance of identifying individualized traits to deliver personalized treatments. Bafadhel et al. extended this work by investigating the utility of peripheral blood eosinophils to direct oral corticosteroid treatment during acute exacerbations of COPD. In an RCT comparing biomarker-directed treatment of acute COPD exacerbations compared to standard care 164 participants were recruited; 55 and 54 patients allocated to the biomarker-driven treatment and standard care groups, respectively. The primary outcome of non-inferiority of health status in the standard therapy and biomarker-directed groups after 2 weeks of treatment was achieved (Chronic Respiratory Questionnaire mean score change, 0.8 vs. 1.1; mean difference, 0.3 [95% CI: 0.0–0.6],  $p = 0.05$ ). Further, there were more treatment failures in the standard care group versus the biomarker directed group and no differences in FEV1 or % improvement in a visual

analogue scale.<sup>57</sup> This study suggests targeted corticosteroid treatment of acute exacerbations is safe and has potential to reduce harm in patients characterized with the treatable trait of eosinophilia. It is important to note, however, that this study was conducted in patients with exacerbations managed in the outpatient setting.

Another RCT that involved hospitalized patients with acute COPD exacerbations tested a biomarker driven approach to systemic corticosteroid administration during the exacerbation. Patients were randomized to either eosinophil-guided therapy ( $n = 159$ ) or standard therapy with systemic corticosteroids ( $n = 159$ ). The biomarker driven treatment approach was not inferior to standard care for the primary outcome of days alive and out of hospital within 14 days after recruitment (mean 8.9 days [95% CI: 8.3–9.6]) in the eosinophil-guided group versus (9.3 days [8.7–9.9]) in the control group (absolute difference  $-0.4$  [95% CI:  $-1.3$  to  $0.5$ ];  $p = 0.34$ ). Further there were no differences in treatment failures at 30 days. Systemic corticosteroid exposure, however, was less in the eosinophil-guided group compared to control (2 days (IQR: 1.0–3.0) vs. 5 days (5.0–5.0);  $p < 0.0001$ ).<sup>58</sup> Again, this study suggests that biomarker-driven treatment targeting a treatable trait may reduce harm by minimizing unnecessary treatment and their associated adverse effects.


Further studies involving hospitalized patients are indicated. A recent study conducted by MacDonald et al. examined the relevance of blood eosinophil counts in patients hospitalized due to acute exacerbations of COPD,<sup>59</sup> demonstrating a strong link between increased eosinophil counts and a reduced presence of infection (CRP  $\geq 20$ mg/L or PCR positive). Interestingly, this is one of the first studies in this patient group to highlight the importance of abnormally low eosinophil counts (eosinopenia), which was associated in both the derivation (retrospective) and the validation (prospective) cohorts with poorer clinical outcomes such as longer length of stay and 1-year mortality compared to those with normal or higher levels of eosinophils. The observational nature of this study, however, precludes confirmation of causality by an ‘infective’ phenotype.

Recognizing the potential benefits of phenotyping COPD exacerbations MacDonald et al. have proposed a novel approach to phenotyping during hospitalizations for acute exacerbations of COPD. This approach attempts to describe the aetiologies of acute exacerbations in COPD using the acronym ABCDEFGX in an effort to focus clinician attention on relevant

management issues, which can otherwise be known as ‘traits’, both during the admission and at follow up.<sup>60</sup> The traits proposed in this acronym includes *Airway viral infection, Bacterial infection, Coinfection, Depression/anxiety, pulmonary Embolism, cardiac Failure (or failure of lung integrity – pneumothorax), General environment and X (unknown)*.<sup>60</sup> The authors went on to apply this characterization in a pilot study of 52 patients admitted to hospital with an acute exacerbation of COPD. They identified multiple exacerbation phenotypes and also identified a population at risk of longer hospital length of stay, that being patients who were co-infected with both a bacterial pathogen and virus.<sup>61</sup>

### Applying a treatable traits approach during the hospitalization

Patients admitted to hospital with an acute exacerbation, irrespective of their chronic airway disease are at risk of future exacerbation, protracted recovery,<sup>3,62–64</sup> impaired health status and death.<sup>35</sup> The events are frightening for patients and create disruption to people’s lives. As such the impacts go beyond the days in hospital and the individual. Other family members and their livelihood are also affected.<sup>65</sup> Data also suggest that after a hospitalization patients do not return to their prior baseline health status.<sup>66,67</sup> Identification of treatable traits within the hospital setting for patients with acute respiratory exacerbations can facilitate more accurate identification of exacerbation aetiology, risk factors and targeted management during and following the period of hospitalization. The treatable trait concept, at its very essence, is ‘label-free’, conferring equal relevance to diseases such as asthma, COPD and bronchiectasis. The traits are clinically important, and the period of hospitalisation may facilitate more ready access to test procedures (TIMs) facilitating their identification and initiation of treatment. We propose that a treatable traits strategy can be applied during this acute phase of illness and can aid in recovery and exacerbation prevention. We have identified the traits proposed in the 2016 publication by Agusti et al.<sup>5</sup> that are most relevant in predicting acute exacerbations and have suggested TIMs for each trait, and the recommended treatment (Table 1). To maximize efficiency and provide best practice care, implementation of the treatable traits strategy requires multidisciplinary team approaches. It is important to acknowledge, however, that this is a



**Figure 3.** Theoretical model highlighting the impact of frailty and acute respiratory exacerbations (red lightning bolts) on acceleration of disability in people with chronic respiratory disease. Source: Reprinted with permission of the American Thoracic Society. Copyright © 2019 American Thoracic Society: Singer, JP, Lederer DJ & Baldwin MR (2016), Frailty in pulmonary and critical care. *Ann Am Thorac Soc*, 13(8), 1394–1404. The *Annals of the American Thoracic Society* is an official *Journal of the American Thoracic Society*.

proposal and data to specifically validate such an approach in the inpatient setting are indicated.

In addition to the treatable traits proposed in earlier work, we have also identified potential new traits of particular relevance to acute exacerbations, including frailty and impaired physical function.

### Frailty

Frailty is most commonly defined as an accumulation of physiological deficits across multiple inter-related systems that results in both concurrent functional limitations and vulnerability to new stressors.<sup>68</sup> Within respiratory medicine, frailty may be conceptualized as a driving factor underpinning some observations of heightened accelerations in functional decline and protracted recovery from acute respiratory exacerbations (Figure 3). In COPD, where most of the limited respiratory data has arisen, frailty has been shown to be more common in people with greater age, disease severity, dyspnoea and comorbidity burden. Having frailty is *not* a normal part of healthy ageing and is associated with an increased risk of falls, hospitalizations and disability.<sup>69–72</sup>

While evaluation of frailty is not yet advocated within respiratory medicine guidelines, its prevalence has been estimated as occurring in up to 19% of people with stable COPD,<sup>73</sup> which is almost double that of the general adult community (10%).<sup>68</sup> Episodes of acute illness increase one's susceptibility to having frailty. Recent data suggest that frailty may be present in over 40% of inpatients with AECOPD and independently increase the risk of 90-day respiratory-related readmission or death.<sup>74</sup>

### *Impaired physical function*

Impaired physical function is a trait that can be conceptually distinguished by pathophysiological muscle dysfunction (e.g. low muscle strength or mass, sarcopenia) and/or sub-optimal functional performance (exercise intolerance, physical inactivity/sedentary behavior). Each may occur in isolation or as an interaction with others. Various physiological and behavioural mechanisms may underpin the presence of this trait during acute respiratory exacerbations. These may include factors related to airway or systemic inflammation, systemic corticosteroid use, malnutrition or physical inactivity).<sup>75</sup> Confirmatory evidence to identify such factors at the clinician-patient interface during acute respiratory exacerbations is, however, rare.

Trait identification markers related to impaired physical function may take various forms such as objective evaluation of muscle strength or mass, physical tests of functional performance (e.g. field walking tests, gait speed, chair-stand tests), assessment of physical activity (objective or subjective) or questionnaire-based evaluations of activities of daily living (e.g. Katz index). As no single test represents the full breadth of physical function impairments, multiple testing appears advisable. Composite metrics such as the short performance physical battery (which includes evaluation of gait speed, chair-stand performance and balance)<sup>76</sup> may offer appeal to address multiple domains in a timely manner. No preference should be given to one aspect of impaired physical function over another. Subjective reports of behaviors such as physical activity levels are known to lack accuracy compared to objective measures. A physical examination (i.e. direct observation and recording of performance) by a suitably trained professional is therefore essential to accurately evaluate this trait. Examples of trait identification markers related to impaired physical function are outlined further in

Table 1. It is important to note that, unlike some other traits (e.g. pulmonary traits), various forms of rehabilitation are most commonly utilized to manage impairments of physical function. This means the time of an acute respiratory exacerbation is a potentially suitable opportunity to *detect* this trait, however, *treatment* of this trait will largely take place at a time after discharge from hospital.

## **Conclusions**

Acute exacerbations frequently occur in chronic airway diseases. These events cause dire and long-lasting effects. The need to minimize exacerbations and effectively treat these events if they occur is urgent. This requires innovative approaches to recognizing traits that predict future exacerbations and testing interventions that prevent exacerbations, beyond our armamentarium of current and often ineffective approaches. Personalized approaches to treating exacerbations are also needed. The treatable traits strategy is an approach that recognises clinically important, identifiable and treatable characteristics of disease. It uses biomarkers to identify traits and applies targeted and personalized interventions for the identified traits. Applying this approach in the prevention and treatment of acute exacerbations of airway diseases could potentially advance management and lead to improved patient and economic outcomes. Future research in the acute setting evaluating biomarkers and treatable traits approaches is a current research priority.

## **Acknowledgements**

The authors wish to acknowledge Dr Steven Maltby for his assistance with the literature search, and Dr Tegan Grace for assistance with formatting.

## **Declaration of conflicting interests**


The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: VMM has participated in educational symposia funded by GlaxoSmithKline, AstraZeneca and Menarini and has participated advisory boards for GlaxoSmithKline, AstraZeneca and Menarini. PGG holds an NHMRC Practitioner Fellowship, has participated in educational symposia funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis, and has participated in studies funded by GlaxoSmithKline and AstraZeneca. CO was the recipient of a Lung Foundation Australia/Boehringer-Ingelheim COPD Research Fellowship (2017-18), but reports no conflicts of interest.


## Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

## ORCID iD

Vanessa M McDonald  <https://orcid.org/0000-0001-9890-3408>

Christian R Osadnik  <https://orcid.org/0000-0001-9040-8007>

Peter G Gibson  <https://orcid.org/0000-0001-5865-489X>

## References

- Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. *Lancet (London, England)* 2017; 391: 350–400.
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. *Lancet* 2015; 385(9963): 117–171.
- Chalmers JD, Aliberti S, Filonenko A, et al. Characterization of the ‘frequent exacerbator phenotype’ in bronchiectasis. *Am J Resp Crit Care* 2018; 197(11): 1410–1420.
- Agusti A, Bafadhel M, Beasley R, et al. Precision medicine in airway diseases: moving to clinical practice. *Eur Respir J* 2017; 50(4): pii: 1701655.
- Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. *Eur Respir J* 2016; 47(2): 410–419.
- Gibson PG, McDonald VM and Marks GB. Asthma in older adults. *Lancet* 2010; 376(9743): 803–813.
- McDonald VM, Fingleton J, Agusti A, et al. Treatable Traits: a new paradigm for 21st century management of chronic airway diseases. *Eur Respir J* 2019; 53: pii: 1802058.
- Global-Asthma-Network. *The Global Asthma Report 2018*. Auckland, New Zealand, 2018.
- Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. *J Allergy Clin Immunol* 2015; 135(4): 896–902.
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J* 2014; 43(2): 343–373.
- Reddel HK, Sawyer SM, Everett PW, et al. Asthma control in Australia: a cross-sectional web-based survey in a nationally representative population. *Med J Australia* 2015; 202(9): 492–497.
- Foster JM, McDonald VM, Guo M, et al. ‘I have lost in every facet of my life’: the hidden burden of severe asthma. *Eur Respir J* 2017; 50(3): pii: 1700765.
- McDonald VM, Hiles SA, Jones KA, et al. Health-related quality of life burden in severe asthma. *Med J Australia* 2018; 209(suppl 2): S28–S33.
- Poulos LM, Correll PK, Toelle BG, et al. *Lung disease in Australia: prepared for lung foundation Australia*. Sydney: Woolcock Institute of Medical Research, 2014.
- Ebmeier S, Thayabaran D, Braithwaite I, et al. Trends in international asthma mortality: analysis of data from the WHO mortality database from 46 countries (1993–2012). *Lancet* 2017; 390(10098): 935–945.
- Sweeney J, Brightling CE, Menzies-Gow A, et al. Clinical management and outcome of refractory asthma in the UK from the British thoracic society difficult asthma registry. *Thorax* 2012; 67(8): 754–756.
- Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British Columbia. *Can Respir J* 2010; 17(2): 74–80.
- Hiles SA, Harvey ES, McDonald VM, et al. Working while unwell: workplace impairment in people with severe asthma. *Clin Exp Allergy* 2018; 48: 650–662.
- Forum of International Respiratory Societies. *The global impact of respiratory disease – second edition*. Sheffield: European Respiratory Society, 2017.
- World Health Organisation. *Disease burden and mortality estimates*. Geneva: World Health Organisation; 2016. [https://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/](https://www.who.int/healthinfo/global_burden_disease/estimates/en/) (accessed 17 May 2019).
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. *Lancet* 2012; 380(9859): 2095–2128.
- Lim S, Lam DC, Muttalif AR, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. *Asia Pac Fam Med* 2015; 14(1): 4.
- Khakban A, Sin DD, FitzGerald JM, et al. The projected epidemic of chronic obstructive pulmonary disease hospitalizations over the next 15 years. A population-based perspective. *Am J Resp Crit Care* 2017; 195(3): 287–291.
- Australian Institute of Health and Welfare. *Admitted patient care 2016–17: Australian hospital statistics. Health services series no. 84. Cat. no. HSE 201*. Canberra: AIHW, 2018.
- Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis

- in the UK from 2004 to 2013: a population-based cohort study. *Eur Respir J* 2016; 47(1): 186–193.
26. Ringshausen FC, de Roux A, Diel R, et al. Bronchiectasis in Germany: a population-based estimation of disease prevalence. *Eur Respir J* 2015; 46(6): 1805–1807.
  27. Kreuter M and Cottin V. The threat in chronic lung diseases: acute exacerbations. *Eur Respir Rev* 2017; 26(145): 170075.
  28. Ramsahai JM, Hansbro PM and Wark PAB. Mechanisms and management of asthma exacerbations. *Am J Resp Crit Care* 2019; 199(4): 423–432.
  29. McDonald VM and Gibson PG. Exacerbations of severe asthma. *Clin Exp Allergy* 2012; 42(5): 670–677.
  30. Marks GB, Colquhoun JR, Girgis ST, et al. Thunderstorm outflows preceding epidemics of asthma during spring and summer. *Thorax* 2001; 56(6): 468–471.
  31. Thien F, Beggs PJ, Csutoros D, et al. The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors. *Lancet Planetary Health* 2018; 2(6): e255–e263.
  32. Calverley PMA. Chronic obstructive pulmonary disease exacerbations and lung function decline. mechanism or marker? *Am J Resp Crit Care* 2017; 195(3): 278–279.
  33. Garcia-Sanz MT, Canive-Gomez JC, Senin-Rial L, et al. One-year and long-term mortality in patients hospitalized for chronic obstructive pulmonary disease. *J Thorac Dis* 2017; 9(3): 636–645.
  34. Ho TW, Tsai YJ, Ruan SY, et al. In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study. *PLoS one* 2014; 9(12): e114866.
  35. Halpin D. Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena. *COPD* 2008; 5(3): 187–200.
  36. Chalmers JD. Bronchiectasis exacerbations are heart-breaking. *Ann Am Thorac Soc* 2018; 15(3): 301–303.
  37. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. *Am J Resp Crit Care* 2014; 189(5): 576–585.
  38. McDonald VM, Hiles SA, Godbout K, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. *Respirology* 2019; 24(1): 37–47.
  39. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* 2010; 363(12): 1128–1138.
  40. Fingleton J, Hardy J and Beasley R. Treatable traits of chronic airways disease. *Curr Opin Pulm Med* 2018; 24(1): 24–31.
  41. McDonald VM, Simpson JL, Higgins I, et al. Multi-dimensional assessment of older people with asthma & COPD: clinical management and health status. *Age Ageing* 2011; 40(1): 42–49.
  42. Jameson JL and Longo DL. Precision medicine – personalized, problematic, and promising. *N Engl J Med* 2015; 372(23): 2229–2234.
  43. Gibson PG and McDonald VM. Asthma-COPD overlap 2015: now we are six. *Thorax* 2015; 70(7): 683–691.
  44. Polverino E, Dimakou K, Hurst J, et al. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. *Eur Respir J* 2018; 52(3): pii: 180032.
  45. McDonald VM, Higgins I, Wood LG, et al. Multi-dimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? *Thorax* 2013; 68(7): 691–694.
  46. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. *Lancet* 2002; 30: 1715–1721.
  47. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. *Eur Respir J* 2006; 27: 483–494.
  48. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. *Lancet* 2011; 378(9795): 983–990.
  49. Zhou A, Zhou Z, Zhao Y, et al. The recent advances of phenotypes in acute exacerbations of COPD. *Int J Chronic Obstr* 2017; 12: 1009–1018.
  50. Brightling CE. Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2013; 10 Suppl: S214–S219.
  51. Garcia-Aymerich J, Gómez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. *Thorax* 2011; 66(5): 430–437.
  52. Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The copenhagen general population study. *Am J Resp Crit Care* 2016; 193(9): 965–974.
  53. Alotaibi NM, Chen V, Hollander Z, et al. Phenotyping COPD exacerbations using imaging and blood-based

- biomarkers. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 217–229.
54. Alotaibi NM, Chen V, Hollander Z, et al. Phenotyping and outcomes of hospitalized COPD patients using rapid molecular diagnostics on sputum samples. *Int J Chron Obstruct Pulmon Dis* 2019; 14: 311–319.
  55. Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. *Eur Resp J* 2019; 53(5): pii: 1802014.
  56. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. *Am J Resp Crit Care* 2011; 184(6): 662–671.
  57. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. *Am J Resp Crit Care* 2012; 186(1): 48–55.
  58. Sivapalan P, Lapperre TS, Janner J, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. *Lancet Respir Med* 2019. DOI: 10.1016/s2213-2600(19)30176-6 [published Online First: 2019/05/28].
  59. MacDonald MI, Osadnik CR, Bulfin L, et al. Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD. *Chest* 2019. DOI: 10.1016/j.chest.2019.02.406 [published Online First: 2019/04/13]
  60. Macdonald M, Beasley RW, Irving L, et al. A hypothesis to phenotype COPD exacerbations by aetiology. *Respirology* 2011; 16(2): 264–268.
  61. MacDonald M, Korman T, King P, et al. Exacerbation phenotyping in chronic obstructive pulmonary disease. *Respirology* 2013; 18(8): 1280–1281.
  62. Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. *Am J Resp Crit Care* 2009; 179(5): 369–374.
  63. Donaldson GC, Law M, Kowlessar B, et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. *Am J Resp Crit Care* 2015; 192(8): 943–950.
  64. Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. *Eur Resp J* 2007; 30(3): 452–456.
  65. McDonald VM, Kennington E and Hyland M. Understanding the experience of people living with severe asthma. In: Chung KF, Israel E and Gibson PG (eds) *Eur Respir Monograph*. Sheffield, UK: European Respiratory Society, 2019, pp. 16–29.
  66. Brill SE, Patel AR, Singh R, et al. Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study. *Resp Res* 2015; 16: 16.
  67. Spencer S and Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. *Thorax* 2003; 58(7): 589–593.
  68. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001; 56(3): M146–M157.
  69. Mittal N, Raj R, Islam EA, et al. The frequency of frailty in ambulatory patients with chronic lung diseases. *J Prim Care Community Health* 2016; 7(1): 10–15.
  70. Maddocks M, Kon SS, Canavan JL, et al. Physical frailty and pulmonary rehabilitation in COPD: a prospective cohort study. *Thorax* 2016; 71(11): 988–995.
  71. Singer JP, Diamond JM, Gries CJ, et al. Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation. *Am J Resp Crit Care* 2015; 192(11): 1325–1334.
  72. Jones SE, Maddocks M, Kon SS, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. *Thorax* 2015; 70(3): 213–218.
  73. Marengoni A, Vetrano DL, Manes-Gravina E, et al. The relationship between COPD and frailty: a systematic review and meta-analysis of observational studies. *Chest* 2018; 154(1): 21–40.
  74. Evaluation and impact of frailty in patients with acute exacerbations of COPD. *Thoracic society of Australia and New Zealand annual scientific meeting 2019*. Gold Coast, Australia: Respirology, 2019.
  75. Maltais F, Decramer M, Casaburi R, et al. An official American thoracic society/european respiratory society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. *Am J Resp Crit Care* 2014; 189(9): e15–e62.
  76. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol* 1994; 49(2): M85–M94.
  77. Kupczyk M, ten Brinke A, Sterk PJ, et al. Frequent exacerbators—a distinct phenotype of severe asthma. *Clin Exp Allergy* 2014; 44(2): 212–221.
  78. Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease

- burden: a UK cohort study. *Lancet Respir Med* 2015; 3(11): 849–858.
79. Bizzintino J, Lee WM, Laing IA, et al. Association between human rhinovirus C and severity of acute asthma in children. *Eur Respir J* 2011; 37(5): 1037–1042.
  80. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. *BMJ* 1995; 310(6989): 1225–1229.
  81. McManus TE, Marley AM, Baxter N, et al. Respiratory viral infection in exacerbations of COPD. *Respir Med* 2008; 102(11): 1575–1580.
  82. Perotin JM, Dury S, Renois F, et al. Detection of multiple viral and bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a pilot prospective study. *J Med Virol* 2013; 85(5): 866–873.
  83. Hansbro PM, Beagley KW, Horvat JC, et al. Role of atypical bacterial infection of the lung in predisposition/protection of asthma. *Pharmacol Ther* 2004; 101(3): 193–210.
  84. Choroszy-Krol I, Frej-Madrzak M, Hober M, et al. Infections caused by *Chlamydia pneumoniae*. *Adv Clin Exp Med* 2014; 23(1): 123–126.
  85. Starkey MR, Nguyen DH, Kim RY, et al. Programming of the lung in early life by bacterial infections predisposes to chronic respiratory disease. *Clin Obstet Gynecol* 2013; 56(3): 566–576.
  86. Shorofsky M, Bourbeau J, Kimoff J, et al. Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study. *Chest* 2019. DOI: 10.1016/j.chest.2019.04.132 [published Online First: 2019/06/01]
  87. Sidney S, Sorel M, Quesenberry CP Jr., et al. COPD and incident cardiovascular disease hospitalizations and mortality: kaiser permanente medical care program. *Chest* 2005; 128(4): 2068–2075.
  88. Iyer AS, Bhatt SP, Garner JJ, et al. Depression is associated with readmission for acute exacerbation of chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2016; 13(2): 197–203.
  89. Rennard SI, Locantore N, Delafont B, et al. Identification of five COPD subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. *Ann Am Thorac Soc* 2015; 12: 303–312.
  90. Hoong JM, Ferguson M, Hukins C, et al. Economic and operational burden associated with malnutrition in chronic obstructive pulmonary disease. *Clin Nutr* 2017; 36(4): 1105–1109.
  91. Lopez D, Flicker L and Dobson A. Validation of the FRAIL Scale in a cohort of older Australian women. *J Am Geriatr Soc* 2012; 60(1): 171–173.
  92. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *New Engl J Med* 2004; 350(10): 1005–1012.
  93. Tudor-Locke C, Craig CL, Brown WJ, et al. How many steps/day are enough? For adults. *Int J Behav Nutr Phys Act* 2011; 8(1): 79.
  94. Cordova Rivera L, Gibson PG, Gardiner P, et al. Physical activity and exercise capacity in severe asthma: key clinical associations. *J Allergy Clin Immunol Pract* 2017 in press.
  95. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. *Thorax* 2003; 58(9): 752–756.
  96. Vilaro J, Ramirez-Sarmiento A, Martinez-Llorens JM, et al. Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. *Respir Med* 2010; 104(12): 1896–1902.
  97. Gariballa S and Alessa A. Sarcopenia: prevalence and prognostic significance in hospitalized patients. *Clin Nutr* 2013; 32(5): 772–776.
  98. Landi F, Cruz-Jentoft AJ, Liperoti R, et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from iSIRENTE study. *Age Ageing* 2013; 42(2): 203–209.
  99. Greening NJ, Harvey-Dunstan TC, Chaplin EJ, et al. Bedside assessment of quadriceps muscle by ultrasound after admission for acute exacerbations of chronic respiratory disease. *Am J Respir Crit Care Med* 2015; 192(7): 810–816.
  100. Pitta F, Troosters T, Probst VS, et al. Physical activity and hospitalization for exacerbation of COPD. *Chest* 2006; 129(3): 536–544.
  101. Orme MW, Harvey-Dunstan TC, Boral I, et al. Changes in physical activity during hospital admission for chronic respiratory disease. *Respirology* 2019; 24: 652–657.
  102. Borges RC and Carvalho CRF. Physical activity in daily life in Brazilian COPD patients during and after exacerbation. *COPD* 2012; 9(6): 596–602.
  103. Garcia-Rio F, Rojo B, Casitas R, et al. Prognostic value of the objective measurement of daily physical activity in patients with COPD. *Chest* 2012; 142(2): 338–346.
  104. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a



- population based cohort study. *Thorax* 2006; 61(9): 772–778.
105. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. *Chest* 2011; 140(2): 331–342.
106. McKeough Z, Cheng SWM, Alison J, et al. Low leisure-based sitting time and being physically active were associated with reduced odds of death and diabetes in people with chronic obstructive pulmonary disease: a cohort study. *J Physiother* 2018; 64(2): 114–120.
107. Troosters T, Probst VS, Crul T, et al. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010; 181(10): 1072–1077.
108. Liao WH, Chen JW, Chen X, et al. Impact of resistance training in subjects with COPD: a systematic review and meta-analysis. *Respir Care* 2015; 60(8): 1130–1145.
109. O’Shea SD, Taylor NF and Paratz J. Peripheral muscle strength training in COPD: a systematic review. *Chest* 2004; 126(3): 903–914.
110. O’Shea SD, Taylor NF and Paratz JD. Progressive resistance exercise improves muscle strength and may improve elements of performance of daily activities for people with COPD: a systematic review. *Chest* 2009; 136(5): 1269–83.
111. Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). *Age Ageing* 2014; 43(6): 748–759.
112. Puhan MA, Gimeno-Santos E, Scharplatz M, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2011; 114(10): 1–9.
113. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mis-handling remains common in real life and is associated with reduced disease control. *Res Med* 2011; 105(6): 930–938.
114. Viniol C and Vogelmeier CF. Exacerbations of COPD. *Eur Respir Rev* 2018; 27(147): pii: 170103.
115. Bloom CI, Palmer T, Feary J, et al. Exacerbation patterns in adults with asthma in England. A population-based study. *Am J Respir Crit Care Med* 2019; 199(4): 446–453.
116. Lee J, Tay TR, Radhakrishna N, et al. Nonadherence in the era of severe asthma biologics and thermoplasty. *Eur Res J* 2018; 51(4): pii: 1701836.
117. McNicholl DM, Stevenson M, McGarvey LP, et al. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. *Am J Respir Crit Care Med* 2012; 186(11): 1102–1108.
118. Engelkes M, Janssens HM, de Jongste JC, et al. Medication adherence and the risk of severe asthma exacerbations: a systematic review. *Eur Res J* 2015; 45(2): 396–407.
119. Ozyilmaz E, Kokturk N, Teksut G, et al. Unsuspected risk factors of frequent exacerbations requiring hospital admission in chronic obstructive pulmonary disease. *Int J Clin Pract* 2013; 67(7): 691–697.
120. Agusti A, Calverley PM, Decramer M, et al. Prevention of exacerbations in chronic obstructive pulmonary disease: knowns and unknowns. *Chronic Obstr Pulm Dis* 2014; 1(2): 166–184.
121. Liang L, Cai Y, Barratt B, et al. Associations between daily air quality and hospitalisations for acute exacerbation of chronic obstructive pulmonary disease in Beijing, 2013–17: an ecological analysis. *Lancet Planet Health* 2019; 3(6): e270–e279.